SPC
RNTX

Sigma Planning Corp’s Rein Therapeutics RNTX Stock Holding History

Sigma Planning Corp’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Buy
348,677
+101,400
+41% +$126K 0.01% 877
2025
Q4 		$299K Sell
247,277
-6,550
-3% -$9.03K 0.01% 1027
2025
Q3 		$291K Sell
253,827
-22,950
-8% -$29.1K 0.01% 1042
2025
Q2 		$387K Sell
276,777
-28,398
-9% -$51.1K 0.01% 882
2025
Q1 		$540K Buy
305,175
+68,965
+29% +$145K 0.02% 701
2024
Q4 		$543K Buy
236,210
+23,800
+11% +$72.1K 0.02% 711
2024
Q3 		$752K Buy
212,410
+86,185
+68% +$230K 0.02% 592
2024
Q2 		$350K Buy
126,225
+58,240
+86% +$239K 0.01% 860
2024
Q1 		$451K Buy
67,985
+51,405
+310% +$246K 0.01% 801
2023
Q4 		$50.5K Buy
+16,580
New +$32.3K ﹤0.01% 829

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Sigma Planning Corp's RNTX Position: Q1 2026 in Review

Sigma Planning Corp increased its Rein Therapeutics (RNTX) stake by 41% in Q1 2026, buying an estimated $126K and bringing the position to 348,677 shares worth $453K. The position accounts for 0.01% of the portfolio, ranked #877.

Sigma Planning Corp first reported a position in RNTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $752K in Q3 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Sigma Planning Corp held 348,677 shares of Rein Therapeutics worth $453K as of Q1 2026.
  • Sigma Planning Corp bought 101,400 Rein Therapeutics shares in Q1 2026, an estimated $126K.
  • Rein Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q1 2026, its #877 holding.
  • Sigma Planning Corp first reported a position in Rein Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Sigma Planning Corp's Rein Therapeutics position peaked at $752K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.